Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)

Market Cap	6.68B +59.7%
Revenue (ttm)	1.22B +12.9%
Net Income	196.08M +10.5%
EPS	1.79 +13.3%
Shares Out	109.28M
PE Ratio	34.13
Forward PE	n/a
Dividend	0.16 (0.27%)
Ex-Dividend Date	n/a

Volume	755,000
Average Volume	1,664,202
Open	61.12
Previous Close	61.10
Day's Range	61.12 - 63.17
52-Week Range	33.00 - 86.50
Beta	0.12
RSI	41.42
Earnings Date	Apr 27, 2026

About SHA:688621

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; respiratory tract drug delivery and topical preparation platforms; polypeptide and o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2009
• Employees: 1,359
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688621

Financial Performance

In 2025, SHA:688621's revenue was 1.22 billion, an increase of 12.92% compared to the previous year's 1.08 billion. Earnings were 196.08 million, an increase of 10.53%.